R. Gabel

Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.

T. Hayama, J. O'brien, S. Ozaki, 1999, The Journal of pharmacology and experimental therapeutics.

Heart Failure Augments the Cardiovascular and Renal Effects of Neutral Endopeptidase Inhibition in Rats

N. Trippodo, C. Harvey, M. Asaad, 1991, Journal of cardiovascular pharmacology.

In vivo pharmacology of a novel AT1 selective angiotensin II receptor antagonist, MK-996.

W. Greenlee, A. Patchett, P. Chakravarty, 1995, American journal of hypertension.

In vivo pharmacology of L-159,913, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.

W. Greenlee, P. Siegl, T. W. Schorn, 1995, Clinical and experimental hypertension.

A new method of measuring renal function in conscious rats without the use of radioisotopes.

S. Kivlighn, R. Ranaei, S. Kivlighn, 1996, Journal of pharmacological and toxicological methods.

Effects of BQ-123 on renal function and acute cyclosporine-induced renal dysfunction.

P. Siegl, S. Kivlighn, S. Kivlighn, 1994, Kidney International.

Hypotension induced by growth-hormone-releasing peptide is mediated by mast cell serotonin release in the rat.

M. Reginato, W. D. Matthews, R. Gabel, 1990, Toxicology and applied pharmacology.

In vivo pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for angiotensin AT2 receptors

W. Greenlee, R. Chang, R. Gibson, 1995 .

Hypotension induced by vasopressin antagonists in rats: role of mast cell degranulation.

N. Hanna, A. Silver, R. Gabel, 1990, Toxicology and applied pharmacology.